Betul Akbulut Yagci

Betul Akbulut Yagci

Auto-generated profile, based on publicly available information

Betul Akbulut Yagci

Dokuz Eylül University Faculty of Medicine, Department of Ophthalmology, İzmir, Türkiye

Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 January 2021 in Turkish Journal of Ophthalmology
Verified
Journal Article
Open access
MKMahmut Kaya
Mahmut Kaya
FÖFerit Hakan Öner
Ferit Hakan Öner
BYBetül Akbulut Yağcı
Betül Akbulut Yağcı
FAFerdane Ataş
Ferdane Ataş
TOTaylan Ozturk
Taylan Ozturk
To evaluate the functional and anatomical results of patients with non-infectious intraocular inflammation (IOI) following intravitreal anti-vascular endothelial growth factor (anti-VEGF) injection for the treatment of neovascular age-related macular degeneration (nAMD). The medical records of patients receiving anti-VEGF treatment for nAMD between January 2015 and March 2019 were retrospectively analyzed. Preoperative and postoperative routine ophthalmological examinations, central macular thickness, duration of inflammation, and follow-up time of the patients with non-infectious IOI following anti-VEGF injection were recorded. Non-infectious IOI was determined in 13 eyes (11 eyes with aflibercept, 2 eyes with ranibizumab) of 1,966 patients who received a total of 12,652 anti-VEGF (4,796 aflibercept and 7,856 ranibizumab) injections. IOI was detected after a mean of 7 injections (2-12 injections). All eyes had both anterior chamber reaction (Tyndall +1/+3) and vitritis (grade 1-3). None of the patients had pain, hypopyon, or fibrin reaction. Visual acuity progressed to baseline levels within 28.3 days. Vitritis continued with a mean of 40 days. All patients recovered with topical steroid therapy. In 11 eyes, injection of the same anti-VEGF agent was continued. No recurrence of IOI was observed in any patients. Non-infectious IOI following intravitreal anti-VEGF injection typically occurs without pain, conjunctival injection, hypopyon, or fibrin and responds well to topical steroid therapy. Visual acuity returns to baseline levels within weeks according to the severity of inflammation.

10 October 2021 in International Ophthalmology
Verified
Journal Article
Closed access
PDF file
GAGul Arikan
Gul Arikan
BABetul Akbulut
Betul Akbulut
CUCanan Aslı Utine
Canan Aslı Utine
ZAZiya Ayhan
Ziya Ayhan
MKMahmut Kaya
Mahmut Kaya
UGUzeyir Gunenc
Uzeyir Gunenc


1 December 2023 in Journal of Clinical and Analytical Medicine
Verified
Journal Article
Closed access
BYBetül Akbulut Yağcı
Betül Akbulut Yağcı
HEHüseyin Erdal
Hüseyin Erdal
Aim It is known that inflammatory processes increase the risk of cataract formation. There are no studies examining inflammatory indices in patients with cataract. Therefore, this is the first study that simultaneously investigates the systemic inflammatory response index (SIRI) and pan-immune-inflammation value (PIV) in patients with cataract. Methods Ninety-five patients and 80 healthy controls who were examined at the Ophthalmology clinics of Aksaray University Education and Research Hospital between January 2022 and January 2023 were included in this retrospective study. The neutrophil-to-lymphocyte ratio (NLR), platelet-to-lymphocyte ratio (PLR), lymphocyte-to-monocyte ratio (LMR), systemic immune-inflammation index (SII), SIRI and PIV values were calculated as indicators of the inflammatory process. Results The mean age of the patients was 68.3 ± 12.1 years and 54.7% of cataract patients were females. In the control group, the mean age was 66.5 ± 5.4 years, and 32.5% of the participants were females. There was no significant difference between the patient and control groups in terms of laboratory parameters (P > 0.05). In addition, inflammatory indices were calculated for the patient and control groups. No statistically significant difference was found between NLR, PLR, LMR, SII, SIRI, and PIV between the groups (P > 0.05). Conclusion This study indicates that SIRI and PIV can be used in the evaluation of cataract patients. Therefore, Hemogram parameters and inflammatory indexes created with their combination may contribute to monitoring the progression of cataracts.

1 February 2023 in Turkish Journal of Ophthalmology
Verified
Journal Article
Closed access
MKMahmut Kaya
Mahmut Kaya
TOTaylan Ozturk
Taylan Ozturk
NŞNilüfer KOÇAK ŞAHİN
Nilüfer KOÇAK ŞAHİN
BYBetül Akbulut Yağcı
Betül Akbulut Yağcı
FAFerdane Ataş
Ferdane Ataş
SKSüleyman Kaynak
Süleyman Kaynak
To compare the functional and anatomical outcomes of ranibizumab and aflibercept monotherapies given according to a pro re nata (PRN) protocol in treatment-naive eyes with diabetic macular edema (DME) in a real-life clinical setting. The medical charts of treatment-naive patients with center-involved DME retrieved from our institutional database were reviewed in this retrospective cohort study. A total of 512 treatment-naive eyes with DME underwent either ranibizumab (Group I; 308 eyes) or aflibercept (Group II; 204 eyes) monotherapy and 462 patients were included. The primary outcome was visual gain over 12 months. The mean number of intravitreal injections within the first year was 4.34±1.83 and 4.39±2.12 in Group I and II, respectively (p=0.260). The mean best corrected visual acuity (BCVA) improvement at 12 months was +5.7 and +6.5 ETDRS letters in Group I and II, respectively (p=0.321). However, among eyes with a BCVA score less than 69 ETDRS letters (54% of the study population), visual gain was more prominent in Group II (+15.2 vs. +12.1 ETDRS letters; p<0.001). Statistically significant decreases in central foveal thickness were observed with both ranibizumab and aflibercept monotherapy (p<0.001), with no significant difference between the groups. (p=0.148). No statistically significant difference was found in visual outcomes at 12-month follow-up between ranibizumab and aflibercept monotherapies using a PRN protocol, although there was a tendency toward slightly better functional and anatomic prognosis in the aflibercept arm.

1 April 2025 in Journal of Clinical and Analytical Medicine
Verified
Journal Article
Closed access
BYBetul Akbulut Yagci
Betul Akbulut Yagci
HEHuseyin Erdal
Huseyin Erdal
Aim The present study aims to investigate the prognostic role of hemoglobin, albumin, lymphocyte, and platelet (HALP) score in pseudoexfoliation syndrome (PEXS) patients and its relationship with pseudoexfoliation glaucoma (PEXG) progression. Methods This retrospective study included 58 PEXS and 61 PEXG patients. All groups’ demographic information and hemograms, s were collected from the hospital automation system. The neutrophil-lymphocyte ratio (NLR), platelet-lymphocyte ratio (PLR), systemic immuno-inflammatory index (SII), systemic inflammatory response index (SIRI), pan-immune inflammation value (PIV), and HALP were calculated to both groups. The results were compared among the groups. Results In this study, there were 119 participants in total: 58 patients with PEXS with an average age of 71.3 ± 8.9 years and 61 patients with PEXG with an average age of 71.3 ± 8.9 years (p=0.15). In paired comparisons, it was observed that the NLR, PLR, SII, SIRI, and PIV indices of the groups were not found to be statistically significant (p>0.001). The HALP score value was lower in the PEXG group than the PEXS (4.73 ± 1.99 and 6.3 ± 2.63, respectively) (p<0.001). The AUC of the HALP score for PEXS and PEXG was 0.696. The optimal cut-off value of HALP to predict PEXG was ≤4.23, with 85% sensitivity and 51.7% specificity (95% confidence interval 0,605-0,777, p<0.01). Conclusion It was found that a lower HALP score was significantly associated with PEXG patients and could be an independent prognostic factor. Although this score alone is not sufficient, this study is important in that it may predict the possibility of developing PEXG.